Yuekang Pharmaceutical announced that the company plans to invest the remaining capital raised in the “Marketing Center Construction Project” and the remaining overraised capital from the initial fund-raising project “Marketing Center Construction Project” in 2020 to the new fund-raising project “RSV and Hepatitis B Innovative Drug Research and Development Project”. As of September 30, 2026, the original project had invested 124.29 million yuan, the remaining capital raised was 40.1332 million yuan, and the remaining overfunded capital was 1.153,900 yuan. A total of 41.2871 million yuan was proposed to be raised. The new project has a total investment of 42 million yuan. The implementing entities are the company and two subsidiaries. Phase II clinical research on two innovative drugs, YKYY018 and YKYY013, will be covered by own funds. The matter still needs to be reviewed by the shareholders' meeting.

Zhitongcaijing · 3d ago
Yuekang Pharmaceutical announced that the company plans to invest the remaining capital raised in the “Marketing Center Construction Project” and the remaining overraised capital from the initial fund-raising project “Marketing Center Construction Project” in 2020 to the new fund-raising project “RSV and Hepatitis B Innovative Drug Research and Development Project”. As of September 30, 2026, the original project had invested 124.29 million yuan, the remaining capital raised was 40.1332 million yuan, and the remaining overfunded capital was 1.153,900 yuan. A total of 41.2871 million yuan was proposed to be raised. The new project has a total investment of 42 million yuan. The implementing entities are the company and two subsidiaries. Phase II clinical research on two innovative drugs, YKYY018 and YKYY013, will be covered by own funds. The matter still needs to be reviewed by the shareholders' meeting.